Search research articles
Contact Us
Filters
Showing results (121-130 of 193) with videos related to
Page
of 20
Sort By:
Molecular & Cellular Proteomics : MCP
|
February 28, 2020
Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines
Carolien van Alphen, Jacqueline Cloos, Robin Beekhof, et al.
British Journal of Haematology
|
July 20, 2006
Human soluble TRAIL/Apo2L induces apoptosis in a subpopulation of chemotherapy refractory nodal diffuse large B-cell lymphomas, determined by a highly sensitive in vitro apoptosis assay
Saskia A G M Cillessen, Chris J L M Meijer, Gert J Ossenkoppele, et al.
Iscience
|
September 13, 2022
Targeting histone methylation to reprogram the transcriptional state that drives survival of drug-tolerant myeloid leukemia persisters
Noortje van Gils, Han J M P Verhagen, Michaël Broux, et al.
Blood
|
July 5, 2005
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis
Bronno van der Holt, Bob Löwenberg, Alan K Burnett, et al.
Hemasphere
|
July 14, 2025
Surface downmodulation of TIM3 safeguards healthy cells but not acute myeloid leukemia from CAR T-cell therapy
Jort J van der Schans, Paresh Vishwasrao, Renée Poels, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2017
Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia
Sieghart Sopper, Satu Mustjoki, Deborah White, et al.
Blood Cancer Journal
|
March 28, 2024
Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial
Niek G van der Maas, Jurjen Versluis, Kazem Nasserinejad, et al.
Blood
|
August 24, 2007
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
Hagop M Kantarjian, Francis Giles, Norbert Gattermann, et al.
Immunotherapy
|
November 6, 2013
Procedures for the expansion of CD14(+) precursors from acute myeloid leukemic cells to facilitate dendritic cell-based immunotherapy
Willemijn van den Ancker, Pepijn G J B Wijnands, Jurjen M Ruben, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 9, 2012
Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories
Jan J Cornelissen, Dimitri Breems, Wim L J van Putten, et al.
Page
of 20
Search research articles
Search
Showing results (121-130 of 193) with videos related to
Sort By:
Page
of 20
Molecular & Cellular Proteomics : MCP
|
February 28, 2020
Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines
Carolien van Alphen, Jacqueline Cloos, Robin Beekhof, et al.
British Journal of Haematology
|
July 20, 2006
Human soluble TRAIL/Apo2L induces apoptosis in a subpopulation of chemotherapy refractory nodal diffuse large B-cell lymphomas, determined by a highly sensitive in vitro apoptosis assay
Saskia A G M Cillessen, Chris J L M Meijer, Gert J Ossenkoppele, et al.
Iscience
|
September 13, 2022
Targeting histone methylation to reprogram the transcriptional state that drives survival of drug-tolerant myeloid leukemia persisters
Noortje van Gils, Han J M P Verhagen, Michaël Broux, et al.
Blood
|
July 5, 2005
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis
Bronno van der Holt, Bob Löwenberg, Alan K Burnett, et al.
Hemasphere
|
July 14, 2025
Surface downmodulation of TIM3 safeguards healthy cells but not acute myeloid leukemia from CAR T-cell therapy
Jort J van der Schans, Paresh Vishwasrao, Renée Poels, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2017
Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia
Sieghart Sopper, Satu Mustjoki, Deborah White, et al.
Blood Cancer Journal
|
March 28, 2024
Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial
Niek G van der Maas, Jurjen Versluis, Kazem Nasserinejad, et al.
Blood
|
August 24, 2007
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
Hagop M Kantarjian, Francis Giles, Norbert Gattermann, et al.
Immunotherapy
|
November 6, 2013
Procedures for the expansion of CD14(+) precursors from acute myeloid leukemic cells to facilitate dendritic cell-based immunotherapy
Willemijn van den Ancker, Pepijn G J B Wijnands, Jurjen M Ruben, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 9, 2012
Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories
Jan J Cornelissen, Dimitri Breems, Wim L J van Putten, et al.
Page
of 20